PMID- 15162063
OWN - NLM
STAT- MEDLINE
DCOM- 20041101
LR  - 20151119
IS  - 1424-859X (Electronic)
IS  - 1424-8581 (Linking)
VI  - 104
IP  - 1-4
DP  - 2004
TI  - Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy 
      in ALL (acute lymphoblastic leukemia) cured patients.
PG  - 346-51
AB  - Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in childhood. 
      The improvements of therapies have increased the number of long-term survivors. 
      However, an increased incidence of secondary neoplasias has been observed in this 
      cohort. Our purpose was to evaluate the late effects of cancer therapy in cured 
      patients previously treated for ALL, considering previous reports on the 
      occurrence of gene fusions as putative markers of chromosomal instability. Twelve 
      ALL patients (aged 5 to 16 years) and twelve healthy subjects (aged 18 to 22 
      years) were studied for the presence of ETV6/RUNX1 (TEL/AML1) translocations, 
      which were detected by FISH (fluorescence in situ hybridization). The blood 
      samples were collected months or years after completion of the therapy, and the 
      frequencies of gene fusions in lymphocytes were compared with those obtained 
      retrospectively for bone marrow samples at the time of diagnosis, and also for 
      the control group. It was demonstrated that ETV6/RUNX1 gene fusion was a frequent 
      event (0.59-1.84/100 cells) in peripheral blood lymphocytes from normal 
      individuals and the ALL patients who underwent chemotherapy showed significantly 
      (P = 0.0043) increased frequencies (0.62-3.96/100 cells) of the rearrangement 
      when compared with the control groups (patients at diagnosis and healthy 
      subjects). However, a significant difference was not found between the groups of 
      patients at diagnosis and healthy subjects, when the two patients who were 
      positive for the rearrangement were excluded. Therefore, increased frequencies of 
      ETV6/RUNX1 fusions in ALL cured patients indicate the influence of previous 
      exposure to anti-cancer drugs, and they may represent an important genetic marker 
      for estimating the risk of relapse, or development of secondary neoplasias.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Brassesco, M S
AU  - Brassesco MS
AD  - Departamento de Genetica, Faculdade de Medicina de Ribeirao Preto-USP, 
      Universidade de Sao Paulo, Ribeirao Preto, SP, Brasil.
FAU - Camparoto, M L
AU  - Camparoto ML
FAU - Tone, L G
AU  - Tone LG
FAU - Sakamoto-Hojo, E T
AU  - Sakamoto-Hojo ET
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Cytogenet Genome Res
JT  - Cytogenetic and genome research
JID - 101142708
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TEL-AML1 fusion protein)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Biomarkers, Tumor/*analysis/blood/genetics
MH  - Bone Marrow/pathology
MH  - Cells, Cultured/ultrastructure
MH  - Child, Preschool
MH  - Chromosomes, Human, Pair 12/*genetics/ultrastructure
MH  - Chromosomes, Human, Pair 21/*genetics/ultrastructure
MH  - Combined Modality Therapy
MH  - Core Binding Factor Alpha 2 Subunit
MH  - Cranial Irradiation
MH  - Female
MH  - Humans
MH  - Lymphocytes/ultrastructure
MH  - Male
MH  - Neoplasm, Residual
MH  - Neoplasms, Second Primary/chemically induced/genetics
MH  - *Neoplastic Cells, Circulating
MH  - Oncogene Proteins, Fusion/*analysis/blood/genetics
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/blood/drug 
      therapy/*genetics/pathology/radiotherapy
MH  - Remission Induction
MH  - *Translocation, Genetic
EDAT- 2004/05/27 05:00
MHDA- 2004/11/02 09:00
CRDT- 2004/05/27 05:00
PHST- 2003/08/20 00:00 [received]
PHST- 2003/11/28 00:00 [accepted]
PHST- 2004/05/27 05:00 [pubmed]
PHST- 2004/11/02 09:00 [medline]
PHST- 2004/05/27 05:00 [entrez]
AID - 77514 [pii]
AID - 10.1159/000077514 [doi]
PST - ppublish
SO  - Cytogenet Genome Res. 2004;104(1-4):346-51. doi: 10.1159/000077514.